Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhengzhou University
Patients with relapsed /refractory diffuse large B cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP. Apatinib is a new type of oral tyrosine kinase inhibitor targeting VEGFR-2.The investigators have been proceeding this trial to evaluate the efficacy and safety of Apatinib in the patients with relapsed refractory diffuse large B cell lymphoma.
Age
14–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age range 14-70 years old; ECOG performance status 0-2.
Estimated survival time \> 6 months.
Histological confirmed diffuse large B cell lymphoma.
Have taken first-line chemotherapy regimen and failed.
None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal.
At least one measurable lesion.
None of other serious diseases, cardiopulmonary function is normal.
Pregnancy test of women at reproductive age must be negative.
Patients could be followed up.
None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
Volunteers who signed informed consent.
You may not be if
Disagreement on blood sample collection.
Patients allergic of any of drug in this regimen or with metabolic disorder.
Pregnant or lactating women.
Serious medical illness likely to interfere with participation.
Serious infection.
Primitive or secondary tumors of central nervous system.
Chemotherapy or radiotherapy contraindication.
The evidence of CNS metastasis.
History of peripheral nervous disorder or dysphrenia.
Patients participating in other clinical trials.
Patients taking other antitumor drugs.
Patients estimated to be unsuitable by investigator.
Clareo Health | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
